Affimed N.V. (AFMD)
NASDAQ: AFMD · IEX Real-Time Price · USD
5.03
+0.15 (3.07%)
Apr 26, 2024, 4:00 PM EDT - Market closed
Affimed Revenue
In the year 2023, Affimed had annual revenue of $9.19M, a decrease of -79.10%. Revenue in the quarter ending December 31, 2023 was $458.89K, a -96.13% decrease year-over-year.
Revenue (ttm)
$9.19M
Revenue Growth
-79.10%
P/S Ratio
8.33
Revenue / Employee
$120,980
Employees
76
Market Cap
76.59M USD
Revenue Chart
* The company reports in EUR currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 9.19M | -34.80M | -79.10% |
Dec 31, 2022 | 43.99M | -1.88M | -4.09% |
Dec 31, 2021 | 45.87M | 11.29M | 32.63% |
Dec 31, 2020 | 34.59M | 10.55M | 43.90% |
Dec 31, 2019 | 24.03M | -3.25M | -11.90% |
Dec 31, 2018 | 27.28M | 24.87M | 1,031.03% |
Dec 31, 2017 | 2.41M | -4.23M | -63.70% |
Dec 31, 2016 | 6.64M | -1.57M | -19.10% |
Dec 31, 2015 | 8.21M | 4.12M | 100.71% |
Dec 31, 2014 | 4.09M | -2.90M | -41.50% |
Dec 31, 2013 | 7.00M | 5.45M | 352.11% |
Dec 31, 2012 | 1.55M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionAFMD News
- 3 days ago - Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology - GlobeNewsWire
- 4 weeks ago - Affimed Reports 2023 Financial Results and Operational Progress - GlobeNewsWire
- 5 weeks ago - Affimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024 - GlobeNewsWire
- 7 weeks ago - Affimed Announces 1-for-10 Reverse Stock Split - GlobeNewsWire
- 3 months ago - Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung Cancer - GlobeNewsWire
- 3 months ago - Affimed Announces Leadership Change and Organizational Restructuring - GlobeNewsWire
- 4 months ago - Affimed Announces Sale of Wholly-Owned Subsidiary AbCheck - GlobeNewsWire
- 4 months ago - Affimed Announces Positive Data for AFM24 in Combination with the PD-L1 Checkpoint Inhibitor Atezolizumab in Heavily Pre-treated EGFR-Wildtype Non-Small Cell Lung Cancer Patients - GlobeNewsWire